Relmada Therapeutics, Inc. (RLMD) SEC Filings — 2025
21 SEC filings for Relmada Therapeutics, Inc. (RLMD) in 2025.
Filings
- Relmada Therapeutics Reports Director/Officer Changes & Financials — 8-K · Dec 15, 2025
- Relmada Narrows Losses, Pivots Pipeline with $94M Capital Infusion — 10-Q · Nov 13, 2025
- Relmada Therapeutics Enters Material Definitive Agreement — 8-K · Nov 5, 2025
- Relmada Therapeutics Files 8-K Report — 8-K · Nov 4, 2025
- Relmada Therapeutics Updates Principal Executive Offices — 8-K · Sep 17, 2025
- Aurorium to Acquire Relmada Therapeutics for $100M — 8-K · Sep 16, 2025
- Relmada Therapeutics Relocates Principal Offices — 8-K · Sep 10, 2025
- Relmada Therapeutics Files 8-K — 8-K · Sep 2, 2025
- RELMADA Remains Pre-Revenue, NASDAQ Listed — 10-Q · Aug 7, 2025
- Relmada Therapeutics Faces Delisting Concerns — 8-K · Jul 23, 2025
- Relmada Therapeutics Terminates Material Agreement — 8-K · Jul 10, 2025
- Aptinyx to Acquire Relmada Therapeutics — 8-K · Jun 18, 2025
- Relmada Therapeutics Files 8-K — 8-K · May 27, 2025
- Relmada Therapeutics Files Q1 2025 10-Q — 10-Q · May 12, 2025
- Relmada Therapeutics Files 8-K — 8-K · Apr 28, 2025
- Relmada Therapeutics Files Proxy Statement — DEF 14A · Apr 11, 2025
- Relmada Therapeutics Files 2024 Annual Report — 10-K · Mar 27, 2025
- Relmada Therapeutics Files 8-K with Key Agreements and Equity Sales — 8-K · Mar 26, 2025
- Relmada Therapeutics Files 8-K: Material Agreement and Disclosures — 8-K · Feb 6, 2025
- Relmada Therapeutics to Transfer Listing to OTCQB — 8-K · Jan 27, 2025
- Relmada Therapeutics Files 8-K: Board, Officer, and Compensation Updates — 8-K · Jan 6, 2025